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Abstract
Objective To estimate the probability of becoming high risk for
cardiovascular disease among people at low and intermediate risk and
not being treated for high blood pressure or lipid levels.
Design Observational study.
Setting General communities in Japan and the United States.
Participants 13 757 participants of the Tokyo health check-up study
and 3855 of the Framingham studies aged 30-74 years with complete
data on risk equation covariates, not receiving blood pressure or
cholesterol lowering treatment, and with an estimated risk of
cardiovascular disease <20% within 10 years. We stratified participants
on the basis of baseline risk: <5%, 5-<10%, 10-<15%, and15-<20%.We
used follow-up measurements from the Tokyo study done annually over
three years (2006-10) and follow-up visits in the Framingham study done
between eight (1968-75) and 19 years (1990-1995) after baseline.
Main outcome measure Estimated 10 year risk of a cardiovascular
event >20% using the Framingham equation.
Results At baseline most participants had <5% risk (60.6% of Tokyo
cohort and 45.7% of Framingham cohort) or 5-<10% risk (24.0% and
28.0%, respectively) of a cardiovascular event within 10 years. There
was <10% probability of crossing the treatment threshold at 19, 8, and
3 years for baseline risk groups <5%, 5-<10%, and 10-<15%,
respectively, and >10% probability of crossing the treatment threshold
at one year for the 15-<20% baseline risk group.
Conclusions Decisions on the frequency of remeasuring for
cardiovascular risk should be made on the basis of baseline risk. Repeat
risk estimation before 8-10 years is not warranted for most people initially
not requiring treatment. However, remeasurement within a year seems
warranted in those with an initial 15-<20% risk.
Introduction
Clinical guidelines increasingly recommend starting therapy to
lower blood pressure or cholesterol on the basis of an
individual’s overall absolute risk of cardiovascular disease1-6
using risk prediction scores such as the Framingham equation.7
For example, in the United Kingdom, clinicians are advised to
start treatment for patients with an estimated 10 year risk of
cardiovascular disease that is 20% or greater,3 4 whereas in
Europe the treatment threshold is an estimated 10 year risk of
fatal cardiovascular disease of 5% or greater.5Guidelines in the
United States use a threshold of 20% risk of cardiovascular
disease over 10 years as part of a decision algorithm for
recommending cholesterol lowering treatment8 but do not
currently use absolute risk for recommending blood pressure
lowering treatment.9 Updated guidelines for the treatment of
raised blood pressure, cholesterol level, and obesity, as well as
an “integrated cardiovascular risk reduction” guideline are being
formulated under the direction of the National Heart, Lung, and
Blood Institute.10 Other countries, such as Australia and New
Zealand, use an estimated five year risk of cardiovascular disease
of 15% as the recommended treatment threshold.1 2
For those who do not meet the treatment threshold, guidelines
differ in their recommendations for repeat risk estimation. In
people at low risk (<10% 10 year risk, <5% five year risk) of
cardiovascular disease repeat estimation is recommended at
least every two years,11 five years,3 4 or 5-10 years2; for people
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at intermediate risk (10-20% 10 year risk, 5-15% five year risk)
of cardiovascular disease repeat estimation is recommended
every 3-6 months,6 6-12 months,11 or five years.2-4 The European
guidelines do not recommend a monitoring interval at all for
any risk group.5 This lack of uniformity in guidance reflects an
absence of evidence on optimal timing of repeat risk estimation,
with expert opinion informing recommendations instead. Repeat
risk estimations that are more frequent than necessary waste
scarce health resources resulting from more clinic visits and
unnecessary laboratory tests. There is also an increased
likelihood of false positive test results, where people are wrongly
identified as being at high risk (>20% 10 year risk). Such people
may start unnecessary treatment, be subjected to more tests and
evenmore frequent follow-up, and experience the psychological
distress from being labelled at high risk of a cardiovascular
event.
Using data collected in two large observational studies we
estimated the probability of crossing a treatment threshold of
20% 10 year risk for those initially below this threshold.
Methods
To assess risk estimation across a wide breadth of time, we used
two cohorts: the Tokyo health check-up study, of medium
duration (1-3 years), and the Framingham studies of longer
duration (8-19 years). In both cohorts low proportions of
participants were taking drugs to lower blood pressure or
cholesterol levels, which enabled observation of the natural
progression of untreated cardiovascular risk over time.
Tokyo health check-up study
The selection of participants in the Tokyo health check-up study
has been described previously.12 We included participants who
first attended the health check-up programme at the Centre for
Preventive Medicine, St Luke’s International Hospital, Tokyo,
Japan between January 2005 and December 2007. Around 80%
of the participants and their dependents are employees of various
companies and local government organisations in Tokyo and
costs are paid for by the employer. The remaining 20% of
participants are citizens of Tokyo who individually registered
for the programme and paid for it without company sponsorship.
Participants were eligible for the current study if they were
screened at least four times in 2005-10, were aged 30 to 74
years, had complete data on risk equation covariates, were not
receiving treatment to lower blood pressure or cholesterol levels,
and had an estimated risk of cardiovascular disease within 10
years that was less than 20% (using the Framingham equation7).
Of a total 75 790 people who met these eligibility criteria and
who attended the baseline visit, we excluded 62 033 because
they did not attend all three subsequent annual follow-up visits.
The resulting study sample had 13 757 participants. Table 4 in
the supplementary file compares those who were included with
those who were excluded. No important differences were
observed between the two groups.
Framingham study
The design and selection criteria for the original Framingham
Heart Study and the Framingham Offspring Study have been
described previously.13 14 Participants were eligible for the
present study if they were free from cardiovascular disease when
attending the 11th examination visit of the original cohort
(1968-71), or the first (1971-75) examination visit of the
offspring cohort, were aged 30 to 74 years, had complete data
on risk equation covariates, were not receiving treatment to
lower blood pressure or cholesterol levels, and had an estimated
risk of cardiovascular disease within 10 years that was less than
20% (using the Framingham equation7). The resulting study
sample had 3855 participants.
Follow-up
For both studies, follow-up visits were used where data were
available to allow calculation of cardiovascular risk. For the
Tokyo study this was approximately yearly visits between 2005
and 2010. For the Framingham Heart Study, this was the 15th
(1977-79) and 20th (1986-90) examination visits, and for the
offspring study this was the second (1979-83), third (1983-87),
fourth (1987-91), and fifth (1991-95) examination visits. Those
who developed cardiovascular disease during the period of
follow-up without crossing the treatment threshold were omitted
from the analysis at later time points.
Measurement of risk factors
In the Tokyo study, blood pressure measurements were taken
in the sitting position by trained nurses; blood pressure
measurements were made twice, once after sitting quietly for
several minutes and then again after at least two minutes. The
average of the two readings was recorded as the participant’s
blood pressure. A fully automatic calibrated oscillometric blood
pressure measuring device (BP-203 RV II, Colin, Japan) was
used with a standard arm cuff. In Framingham, blood pressure
measurements were made on the left arm of the seated
participants with a mercury column sphygmomanometer and
an appropriately sized cuff; the average of two doctor obtained
measures constituted the examination blood pressure.
In both studies serum total and high density lipoprotein
cholesterol levels were determined with standardised enzymatic
methods. Cigarette smoking status was ascertained by self report.
Diabetes was defined as fasting glucose ≥126 mg/dL15 or use
of insulin or oral hypoglycaemic drugs. Blood pressure and
cholesterol lowering treatment was based on self report (Tokyo
and Framingham) and ascertained by the doctor examiner at the
heart study (Framingham16).
Statistical analysis
For each individual we calculated their estimated risk of
cardiovascular disease within 10 years (based on the
Framingham risk equation7) at each time point. Where the
measurement of systolic blood pressure (90-200 mm Hg), high
density lipoprotein cholesterol (10-100 mg/dL), or total
cholesterol (100-405 mg/dL) fell outside of the ranges used by
the Framingham online risk calculator, we used the minimum
or maximum limit as is recommended.17 To deal with the
problem of ages outside of the recommended range, we did
additional analyses restricted to people who were aged 74 years
or less at the final follow-up visit.
Some people started treatment during the follow-up period,
which may have partially negated the increase in risk that would
otherwise have occurred. To allow for this, we estimated their
blood pressure or cholesterol level subsequent to the time
treatment was started by adding the mean increase in risk found
in treatment naive patients to the last risk estimate before the
patients started treatment.
We defined four subgroups of people based on baseline risk:
<5%, 5-<10%, 10-<15%, and 15-<20% 10 year risk. We
calculated the point prevalence of crossing the 20% treatment
threshold at time points of 1, 2, and 3 years (Tokyo study) and
8, 12, 16, and 19 years after initial assessment (Framingham
study, median follow-up times for data used). We used the point
prevalence estimates to plot the estimated probability of crossing
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the treatment threshold over time. Within the risk groups, we
also conducted analyses stratified by decade of age (30-39 years,
40-49 years, 50-59 years, 60-69 years, and ≥70 years), to
determine whether the risk of crossing the treatment threshold
depended on age independent of baseline risk.
Results
Table 1⇓ summarises the baseline characteristics of the two
cohorts. At baseline most of the participants in both studies
were at very low risk (60.6% and 45.7% of Tokyo and
Framingham cohorts, respectively, had <5% risk) or low risk
(24.0 and 28.0% of Tokyo and Framingham cohorts had 5-<10%
risk).
The number of participants who started blood pressure and
cholesterol lowering treatment during follow-up in the two
studies was generally low, reaching a maximum of around one
third of participants in the Framingham study after 19 years of
follow-up (see supplementary table 1 for detailed results).
Probability of crossing 20% threshold 1-3
years (Tokyo cohort)
Table 2⇓ displays the probability of people crossing the
treatment threshold for the four baseline risk groups. The
probability of crossing the treatment threshold was <1% for
both the very low baseline risk (<5%) and the low baseline risk
(5-<10%) groups after three years. The probability of crossing
the threshold for the intermediate baseline risk (10-<15%) group
was <10% (5.7%, 95% confidence interval 4.5% to 7.0%) at
three years, whereas for the high intermediate baseline risk
(15-<20%) group it was >10% at one year (16.1%, 13.4% to
19.0%).
Overall, 79 participants developed cardiovascular disease during
the three years of follow-up; of these only three had crossed the
20% threshold before clinical disease.
Probability of crossing 20% threshold 8-19
years (Framingham cohort)
Supplementary figure 1 summarises the number of people with
data available for risk estimation at each follow-up visit. For
visits at eight and 19 years of follow-up, data were available
from both the Framingham Heart Study and the Framingham
Offspring Study, but for visits at 12 and 16 years data were only
available from the offspring study (and consequently there are
fewer participants at these visits).
Table 2 displays the probability of people crossing the treatment
threshold for the four baseline risk groups. The probability of
crossing the treatment threshold for the very low baseline risk
(<5%) group was <10% at 19 years of follow-up (6.8%, 5.5%
to 8.2%). The probability of crossing the treatment threshold
for the low baseline risk (5-<10%) group was <10% at eight
years (9.1%, 7.1% to 11.3%). Finally, for the intermediate
baseline risk (10-<15%) and high intermediate baseline risk
(15-<20%) groups it was >10% at eight years (32.1%, 27.6%
to 36.8% and 73.5%, 67.2% to 79.1%, respectively).
Estimates for the age restricted analysis (<74 years at last
follow-up) were similar to those reported above (data not
shown). The analysis by decade of age within risk subgroups
(see supplementary figure 2) suggests that the interval between
remeasurement does not depend strongly on age once allowing
for baseline risk.
The figure⇓ summarises the probability of crossing the 20%
treatment threshold across the 19 years of follow-up available
from the two cohorts, as well as estimates of measurement
variability from the National Health and Nutrition Examination
Survey (see supplementary file for further details on results
from this study).
The estimate of variability from the National Health and
Nutrition Examination Survey data is based on repeat
measurements made over a few weeks where there is unlikely
to be any true change in the individual’s underlying risk. The
considerable variability in risk seen over the short term is
possibly due to the measurement error and short term variability
in blood pressure and lipid levels, which are then magnified by
the multiplicative nature of the Framingham risk equation.
Discussion
Our findings suggest that the decision on when to rescreen
people’s risk of cardiovascular disease should be decided
according to their baseline risk and that for most individuals it
may be done at a much longer interval than currently
recommended. Less than 10% of those in the lowest baseline
risk group (<5%) would be over the risk threshold even at 19
years. Those with low baseline risk (5-<10%) also had a low
probability of crossing the treatment threshold early on, with
9% crossing the threshold after eight years. Together these two
groups made up over 75% of each study population
examined—that is, over three quarters of the population had
<10% baseline risk. It is likely that populations who are not
receiving treatment in the wider community will be also
concentrated in the very low and low risk end of the risk
continuum and so for most patients frequent monitoring is not
needed.
The results of the low risk groups contrast with those in the
intermediate risk (10-<15%) and high intermediate risk
(15-<20%) groups, of whom 32.1% and 73.5% had crossed the
threshold by eight years of follow-up, indicating that
remeasurement before this time is indicated. The probability of
crossing the threshold for the intermediate risk (10-<15%) group
was only 5.7% after three years, and so clinicians may choose
to wait longer to remeasure risk.
Whereas the probability of crossing the 20% risk threshold
increases progressively over years 1 to 3 for the three groups
below 15% baseline risk, the probability of crossing the 20%
threshold seems to decrease in those at 15-<20% baseline risk,
from 16.1% at one year to 11.3% at three years. We do not think
this is biologically plausible and is likely to be a chance finding.
For all years a large part of this is likely to be due to
measurement variability rather than to a true increase in
underlying risk: there is a probability of at least this magnitude
(19%) of crossing the threshold if remeasurement is done after
only a fewweeks (see NHANES estimates in the supplementary
file). The examples in supplementary table 2 show how even
minor changes in risk factors can change people over the
threshold.While it is clear that the high-intermediate risk group
warrant closer follow-up than those in the lower risk groups,
the optimum time interval for remeasurement remains uncertain.
Comparison with other studies
Although this seems to be the first study on the timing of
rescreening of people who are initially below a risk threshold
for cardiovascular disease, this echoes previous work that has
looked at individual risk factors such as cholesterol, blood
pressure, and HbA1c. The mean blood pressure of patients in the
PROGRESS (perindopril protection against recurrent stroke
study) cohort did not change during the 33 month follow-up.18
However, random drift of patients did vary around this average:
by the 33 months around 20% may have had a true increase (or
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decrease) of at least 10 mm Hg, suggesting that monitoring
every 2-3 years might be reasonable. Similarly, in a six year
follow-up of the LIPID (Long-term Interventionwith Pravastatin
in Ischaemic Disease) trial patients, there was only a slow
average increase in lipid levels, but the variation between
patients might warrant remeasurement every three years.19 For
both blood pressure and cholesterol levels, modelling suggested
that the appropriate interval depended on how close the current
level was to an action threshold that might warrant further
treatment. This relation to initial level was empirically confirmed
in a large Japanese cohort, which showed that the chance of
crossing a risk factor threshold depended strongly on the initial
level for cholesterol,12 blood pressure,20 and HbA1c.
21 Although
these studies used different methods and are not directly
comparable, the appropriate intervals for reassessing risk of
cardiovascular disease seem to be even longer.
Strengths and weaknesses of this study
Although the findings here are likely to be reasonably robust
(based on a large group of people with little drop-in to treatment
and covering a long duration) there are some weaknesses and
limitations. Firstly, our findings are based on two different
cohorts with differing lengths of follow-up. The gap in follow-up
between data from the two studies (no measurements are
available between three and eight years of follow-up) makes it
difficult to know when those with 15-<20% baseline risk first
cross the treatment threshold with a greater probability than that
due to measurement variability. Secondly, the estimated
proportion of individuals above threshold was based on those
who attended each clinic visit. The Japanese cohort was selected
in a way such that all participants attended each of the three
annual follow-up visits; however, in the Framingham cohort
participants were missing at each of the follow-up visits. Those
who fail to attend follow-up may be at higher risk of crossing
the threshold than those who do attend. As follow-up in the
Framingham study is likely to be at least as good as in clinical
practice, our estimates for probability of crossing the threshold
over the longer term may be generalised to the clinical setting.
Thirdly, the small numbers in the higher risk groups mean that
our estimates have greater uncertainty than with the group at
low initial risk of cardiovascular disease. Although the
Framingham and Japanese cohorts seem reasonably consistent,
the generalisability across countries and subgroups is uncertain
and verification in other cohorts is warranted. Finally, we have
only focussed on the intervals betweenmeasurement of absolute
risk for the purposes of initiating drug treatment. Other intervals
may be more appropriate for the assessment of patients for the
purposes of assessing the need for intensifying lifestyle
modifications, such as weight loss and smoking cessation.
Conclusions
The assessment of absolute cardiovascular risk has become an
important guide for when to initiate preventive drug treatments.
However, there has been little discussion or work on how often
such assessments need to be done. These analyses suggest two
main conclusions: the interval between assessments can safely
be longer than generally suggested, but this interval should
depend on the assessed level of risk. Unless there is a clear
trigger, such as starting smoking, major dietary change, or
substantial weight gain, those at low initial cardiovascular risk
can be reassessed in several years. Future guidelines should
incorporate these findings and provide reassessment intervals
stratified by initial cardiovascular risk.
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Tables
Table 1| Baseline characteristics of two cohorts. Values are numbers (percentages) unless stated otherwise
Framingham study (n=3855)Tokyo health check-up (n=13 757)Characteristics
1590 (41.2)6533 (47.5)Men
45.7 (10.5)47.8 (9.8)Mean (SD) age (years)
209.3 (40.1)204.0 (33.4)Mean (SD) total cholesterol (mg/dL)
53.3 (15.5)64.0 (15.9)Mean (SD) HDL cholesterol (mg/dL)
124.2 (15.6)115.8 (15.7)Mean (SD) systolic blood pressure (mm Hg)
1427 (37.0)1318 (9.6)Smoker
71 (1.8)258 (1.9)Diabetes
Baseline risk:
1762 (45.7)8342 (60.6)<5%
1079 (28.0)3297 (24.0)5-<10%
622 (16.1)1409 (10.2)10-<15%
392 (10.2)709 (5.2)15-<20%
HDL=high density lipoprotein.
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Table 2| Probability of crossing 20% cardiovascular disease risk threshold at increasing time intervals. Values are percentage of participants
above threshold (95% confidence interval)
Years 8-19 (Framingham study)Years 1-3 (Tokyo health check-up)Baseline
risk 19 years16 years12 years8 years3 years2 years1 year
6.8 (5.5 to 8.2)*3.7 (2.8 to 4.9)1.0 (0.5 to 1.6)0.5 (0.2 to 1.0)0.05 (0.01 to 0.12)0.01 (0.00 to 0.07)0.0 (0.00 to 0.04)<5%
39.7 (35.8 to 43.6)†33.2 (28.9 to 37.7)†16.4 (13.2 to 20.0)*9.1 ( 7.1 to 11.3)*0.70 (0.45 to 1.05)0.43 (0.23 to 0.71)0.15 (0.05 to 0.35)5-<10%
82.6 (77.4 to 87.0)†70.9 (63.3 to 77.7)†52.5 (45.0 to 59.9)†32.1 (27.6 to 36.8)†5.7 (4.5 to 7.0)*3.6 (2.7 to 4.8)1.4 (0.9 to 2.2)10-<15%
92.8 (86.8 to 96.7)†91.2 (80.7 to 97.1)†88.4 (78.4 to 94.9)†73.5 (67.2 to 79.1)†11.3 (9.05 to 13.9)*14.0 (11.53 to
16.8)*
16.1 (13.4 to 19.0)*15-<20%
*Moderate chance 5-20%.
†High chance >20%.
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Figure
Probability of crossing 20% cardiovascular disease treatment threshold for 10 year cardiovascular event risk over 19 years
of follow-up
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